Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat A Fresh IPO That Long-Term Investors Shouldn't IgnoreAuthor: Jordan Chussler. Article Published: 1/14/2026. 
Summary - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful of them can offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. But even conservative investors shouldn't automatically dismiss newly public stocks — some may merit a place in buy-and-hold portfolios. One biotechnology company in the healthcare sector that recently went public could be an example of that. Last Year's IPO Success Stories Last year provides a clear example of why newly public companies deserve attention, even from investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have capitalized on its nearly 359% gain before the stock reached 30 days on the Nasdaq, but longer-term holders are still seeing strong returns. Other listings, such as Medline (NASDAQ: MDLN), challenge the notion that IPOs are all high‑risk startups. The medical products and services provider, which debuted publicly in December 2025, was founded in 1966 and already has a market cap exceeding $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—known for its ubiquitous bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44%, or $1 per share annually, making it an immediate consideration for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals — a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that seeks out specific cells (for example, cancer cells) to deliver localized doses of radiation. That targeted approach helps minimize harm to healthy tissue compared with some conventional radiation therapies. Industry consultancy Grand View Research estimated the global nuclear medicine market at nearly $18 billion in 2024 and forecasts it will reach nearly $35 billion by 2030, a compound annual growth rate of about 10.16%. Importantly for Boston-based Aktis Oncology, Grand View Research notes that North America accounts for almost 43% of the global nuclear medicine market, with the United States the dominant regional player. Aktis Oncology's Clinical-Stage Biotechnology Wall Street expects biotech IPO activity to rebound in 2026 after funding reductions notably slowed listings from the healthcare sector in 2025. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and produced one of the larger raises for a biotech in recent memory. With $318 million in IPO proceeds, the firm opened with a market cap of about $3.34 billion. According to the company's prospectus, the executive team includes experienced drug developers and commercial leaders; members of management have participated in bringing 14 currently FDA‑approved products to market. Specifically, Aktis develops targeted alpha radiopharmaceuticals, a new class of precision oncology drugs that use proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Notably, the firm is a clinical‑stage, pre‑revenue company, but that did not stop it from attracting attention from Eli Lilly (NYSE: LLY), which anchored its IPO. According to Reuters, Eli Lilly purchased $100 million of AKTS shares in the offering. That investment builds on a 2024 partnership between the two companies to develop tumor‑targeting radiopharmaceuticals. As part of that earlier deal, Aktis received $60 million in cash and an equity investment from Eli Lilly, with potential milestone payments that could exceed $1 billion. The significance of Eli Lilly's backing should not be understated. With a market cap around $1.01 trillion, Eli Lilly is one of the largest pharma companies by market value, and its net income jumped nearly 109% year‑over‑year from 2023 to 2024. Between its equity stake and the recent $100 million purchase of AKTS shares, the maker of Zepbound now has a meaningful financial interest in the biotech startup's success. Investors should remember that Aktis is still pre‑revenue and clinical‑stage, so the upside potential is paired with substantial risk. The Eli Lilly partnership and the size of the IPO proceeds, however, give the company resources and industry validation that may be important as it advances its drug candidates through development and regulatory review.
| 
